Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »

5/36 von 412 DIMDI: MEDLINE (ME66) © NLM

ND: | ME16582688
PMID: | 16582688
CED: | 20060403
Autoren: | Hogenmiller MS; Lozada CJ
Titel: | An update on osteoarthritis therapeutics.
Quelle: | Current opinion in rheumatology; VOL: 18 (3); p. 256-60 /200605/
PM: | Print
SU: | IM
Sprache: | English
CY: | United States
JID: | 9000851
ISSN: | 1040-8711
CO: | CORHES
Institution: | aDepartment of Medicine, Jackson Memorial Hospital bDepartment of Medicine, Miami VA Medical Center cDivision of Rheumatology, University of Miami Miller School of Medicine, Miami, Florida, USA.
DT: | Journal Article
AB: | PURPOSE OF REVIEW: This review addresses recent major developments in symptomatic therapy and the principles of disease modification in osteoarthritis. It emphasizes issues that are of importance to the practicing clinician at a time when researchers in the field are trying to improve ways not only to provide symptomatic relief but also to slow disease progression. RECENT FINDINGS: The past year has led to a reassessment of the role of cyclo-oxygenase-2 inhibitors in osteoarthritis therapy and has yielded new information on nutriceuticals such as glucosamine. The relative efficacy of intra-articular injections of agents such as corticosteroid and hyaluronic acid preparations has been assessed. In addition, reports on trials of potentially disease-modifying agents for osteoarthritis have been published. SUMMARY: Because the therapeutic options have been reduced over the past year and the role of nutritional supplements remains unclear, the clinician is faced with a need to reassess osteoarthritis therapy. Although no practical disease-modifying agent for osteoarthritis has been identified, reports such as the recent doxycycline trial reviewed herein provide hope that continued research will soon yield a therapeutic model similar to that used in rheumatoid arthritis, for which some therapeutic agents achieve disease modification and other agents can be added as needed for symptomatic relief.

» Volltext »
» Fenster schließen »